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the forces promoting the rapid adoption of EVAR by sur-
geons and others—namely, the excitement of being
involved in a new procedure, the hype, the desire to obtain
personal and institutional prestige, and financial gains for
surgeons and device manufacturers.
Within the context of their review, most of their points
are correct, and surgeons using EVAR should pay them
heed. We agree that EVAR should not generally be used
to treat AAAs <5.5 cm in diameter unless the AAA is
clearly enlarging, tender, or present in a small woman.
EVAR should still be considered investigational and under
evaluation and some form of audited follow-up for the life
of all patients is mandatory. Prospective, randomized trials
comparing EVAR with open AAA repair are justified in
standard risk patients. In unfit, high-risk patients, EVAR
should be compared in a randomized trial with best non-
operative management. Such trials are underway in the
United Kingdom, the United States, and the Netherlands,
although only in the United Kingdom is a high-risk trial
planned. These trials, which will establish accurate indica-
tions for EVAR, should be supported.
However, we cannot accept the editorial’s conclusion
that EVAR is “a failed experiment.” This conclusion
would suggest the abandonment of EVAR, which would
be a mistake. The history of surgical innovation is based
on progress through the development of new technology,
application of surgical intuition to perfect a procedure,
and selection of appropriate patients. Just because an
innovation is new or imperfect or has risks does not mean
it should be abandoned. Airplanes, jet engines, blood
transfusions, and other innovations had early problems,
yet all eventually proved advantageous. EVAR will eventu-
ally prove to have value in selected (but not all) patients.
Better devices and improved patient selection will almost
certainly lead to improved results. Thus, EVAR is certainly
here to stay, even though its precise role remains to be
defined. EVAR is not a failed experiment; it is an innova-
tion in evolution and under evaluation.
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A recent editorial in the British Journal of Surgery,
entitled “Endovascular treatment of abdominal aortic
aneurysm: A failed experiment,” makes some worthy
points but overlooks how surgical developments evolve.1
It should be required reading for all vascular surgeons and
others engaged in endovascular aneurysm repair (EVAR)
and particularly for those performing EVAR in patients
with small abdominal aortic aneurysms (AAAs) <5.5 cm in
maximal diameter.
The authors of the editorial, J. Collin and J. A. Murie,
correctly point out the low rupture rate of small AAAs
(<1% per year) and comment on the uncertain rupture rate
of large AAAs. They also note the increasing device and
procedural failures with time, the modification or with-
drawal of all proprietary stent-grafts used in EVAR, the
preponderance of small AAAs in most EVAR series, and the
glaring lack of universal follow-up and audited reporting of
late results. They indicate that the smaller AAAs that are
usually treated by EVAR are those that may be easiest to
repair by conventional open surgery and that this group of
patients would have a low open-surgery operative mortal-
ity and require fewer reinterventions than with EVAR.
They summarize the appreciable early and late complica-
tion rates of EVAR, the reintervention and conversion rates
and the relatively high morbidity associated with some of
these secondary interventions. They provide some evi-
dence that EVAR may be more costly than conventional
open AAA repair. They also note that the rupture risk of 1%
per year after EVAR is not greatly different from the nat-
ural history of most of the small AAAs so treated. They
comment on the high 30-day and 1-year mortality rates
when EVAR is employed. They conclude by enumerating
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